Quick answer
After radiotherapy, PSA falls slowly to its lowest point, the nadir. Under the Phoenix criteria, the cancer has come back when PSA rises 2 ng/mL or more above that nadir.1 The next step is to find where it is, with PSMA PET and MRI, and to confirm by biopsy whether the recurrence is in the prostate.2 For selected cases, the European guideline indicates a local salvage treatment, such as salvage radical prostatectomy or brachytherapy.2 I perform salvage prostatectomy when necessary, and the choice is always made case by case.
When a PSA rise counts
Radiotherapy treats the prostate, but the gland stays in place and keeps making a little PSA. That is why PSA does not drop to zero as it does after surgery. In 2005, a consensus of radiation oncologists in Phoenix, in the United States, defined radiotherapy failure as a PSA rise of 2 ng/mL or more above the nadir, with or without hormone therapy.1
The European guideline uses the same definition and notes that it is right more than 80% of the time when the cancer has truly come back.2 After prostatectomy the threshold is different: the level that best predicts metastases is a PSA above 0.4 ng/mL and rising.2 The page on PSA after prostatectomy explains that situation.
Not every PSA recurrence weighs the same
On average, a PSA recurrence comes seven to eight years before metastases appear.2 And the risk varies a lot from one man to another. The European guideline describes two groups:2
| Group | Definition after radiotherapy |
|---|---|
| Low risk | PSA rising more than 18 months after radiotherapy and an initial biopsy with ISUP below 4 |
| High risk | PSA rising within 18 months of radiotherapy or an initial biopsy with ISUP 4 or 5 |
In low risk, monitoring with PSA is an option accepted by the guideline.2
The tests: where is the cancer?
Before treating the prostate again, we need to know whether the cancer is only there. The European guideline recommends:2
- PSMA PET for every patient who could have salvage treatment with curative intent.
- Prostate MRI to locate the suspicious area and guide the biopsy.
- Biopsy to confirm the recurrence in the prostate before any local treatment.
PSMA PET finds more disease the higher the PSA. In a study of 635 men with recurrence after surgery or radiotherapy, it found the disease in 57% with PSA between 0.5 and 1 ng/mL, in 86% with PSA between 2 and 5 ng/mL and in 97% with PSA of 5 ng/mL or more.3
The scan changes decisions a great deal. In a study of 568 men who had reached the Phoenix criteria, PSMA PET showed recurrence only in the prostate in 32% and distant metastases in 49%.2 A man with metastases does not benefit from salvage surgery on the prostate.
MRI shows where to biopsy. In my practice, prostate biopsy is done under sedation, by the transperineal route.
Salvage options for the prostate
When biopsy confirms that the cancer has come back only in the prostate, the 2026 European guideline recommends, for very selected patients:2
| Option | What the guideline recommends |
|---|---|
| Salvage radical prostatectomy | Offer in experienced centres (strong recommendation) |
| Salvage brachytherapy | Offer in experienced centres (strong recommendation) |
| Salvage stereotactic radiotherapy | Offer in experienced centres (strong recommendation) |
| Salvage HIFU | Offer within a clinical trial or well-designed prospective cohort (weak recommendation) |
| Salvage cryotherapy | Offer within a clinical trial or well-designed prospective cohort (weak recommendation) |
No study has randomised patients between these options. A review of 150 studies, MASTER, compared the results and found that at 5 years between 50% (cryotherapy) and 60% (high-dose-rate brachytherapy and stereotactic radiotherapy) of men were free of a new recurrence, with no major difference compared with surgery. Severe urinary side effects were more common after surgery (20%) than after repeat radiotherapy (5.6% to 9.6%).7
A 2026 review of 31 studies and 4,525 men treated with local salvage alone found 55.2% free of hormone therapy at 5 years and 75.2% free of metastases. Severe side effects were 13% after surgery, 14% after low-dose-rate brachytherapy, 5% after HIFU and high-dose-rate brachytherapy, 4% after stereotactic radiotherapy and 2% after cryotherapy.8 The pages on HIFU and cryotherapy explain each technique.
Who can have salvage prostatectomy
Surgery after radiotherapy is harder, because radiation leaves scarring and the tissues heal less well.2 That is why the European guideline reserves salvage prostatectomy for men with:2
- recurrence in the prostate confirmed by biopsy;
- a PSMA PET with no disease in the lymph nodes or at a distance;
- few other illnesses and a life expectancy of at least 10 years;
- PSA below 10 ng/mL before surgery;
- an initial T1 or T2 tumor, with ISUP up to 2 or 3 on the first biopsy.
Among men operated on, those with low-risk PSA recurrence under the European classification stayed free of metastases longer (90% versus 76%) than those at high risk.2
Results and complications of surgery
In a multicentre study of 404 men operated on after radiotherapy, 37% remained free of PSA recurrence at 10 years, 77% free of metastases and 83% alive without dying of the cancer. The factors that mattered most were the PSA before surgery and the Gleason score of the biopsy taken after radiotherapy.5
Complications are more common than in a first prostatectomy. A review of 40 studies found:4
| Effect | Range across studies |
|---|---|
| Narrowing of the bladder-urethra junction | 7% to 41% |
| Rectal injury | 0% to 28% |
| Severe complications | 0% to 25% |
| Continence after surgery | 21% to 90% |
| Erectile dysfunction after surgery | 80% to 100% (50% to 91% already had it before) |
In the same review, complications became less frequent in more recent series, except narrowing.4 The European guideline compares this with open prostatectomy done as first treatment: after radiotherapy, narrowing reached 47% (versus 5.8%) and rectal injury 9.2% (versus 0.6%). These complications seem less common with the robot than with open surgery.2
Robotic salvage surgery has its own literature. A review of 33 series with 1,630 men found complications during surgery in up to 9% and continence and erections well below those of robotic prostatectomy done as first treatment.6 The page on continence explains how bladder control recovers.
Hormone therapy: when to use it and when to wait
With a PSA recurrence, hormone therapy aims to delay metastases and prolong life. A PSA drop alone, without that gain, does not help the patient, and the side effects weigh more in older men and in men with heart disease.2 That is why the European guideline recommends:2
- not offering hormone therapy to men without metastases whose PSA takes more than 12 months to double;
- offering enzalutamide with hormone therapy to men without metastases on conventional imaging whose PSA doubles in 9 months or less, as in the EMBARK trial.
The benefit of starting early shows up mostly in high-risk men: high ISUP, PSA that doubles quickly and a long life expectancy.2
How I approach it
I perform salvage radical prostatectomy after radiotherapy when necessary, always with the robot. The decision is made case by case: I review the initial biopsy, the radiotherapy you had, the PSA curve, the PSMA PET, the MRI and the biopsy that confirmed the recurrence. We talk about the salvage options, what each one offers and the risks, especially for urine control and erections, on top of any radiotherapy side effects you may already have.
I have a PhD from the University of São Paulo Medical School and have performed more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic.
If you had radiotherapy elsewhere and want another assessment, a second opinion can be done entirely online, in English, with your test results sent in advance.
Send your case
If your PSA has risen after radiotherapy and you would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
What PSA rise shows the cancer has come back after radiotherapy?+
Under the Phoenix criteria, used worldwide, radiotherapy failure is a PSA rise of 2 ng/mL or more above the lowest value it reached after treatment, the nadir. This applies to radiotherapy with or without hormone therapy.1 The European guideline uses the same definition.2
My PSA rose after radiotherapy. Do I need treatment right away?+
Not always. The European guideline splits PSA recurrence into low and high risk. In low risk (PSA rising more than 18 months after radiotherapy and an initial biopsy with ISUP below 4), monitoring with PSA is an option. The guideline also recommends not starting hormone therapy when PSA takes more than 12 months to double and there are no metastases.2
Which tests are done when PSA rises after radiotherapy?+
For men who are candidates for salvage treatment, the European guideline recommends PSMA PET, to look for disease outside the prostate, and prostate MRI, to locate the suspicious area and guide the biopsy.2 Before any local salvage treatment, the recurrence in the prostate must be confirmed by biopsy.2
Can the prostate be removed after radiotherapy?+
Yes, in selected patients. The European guideline indicates salvage radical prostatectomy for men with biopsy-confirmed recurrence, no nodal or distant disease on PSMA PET, few other illnesses, a life expectancy of at least 10 years, PSA below 10 ng/mL before surgery and an initial T1 or T2 tumor with ISUP up to 2 or 3, in experienced centres.2
What are the risks of salvage prostatectomy?+
They are higher than with first-time surgery, because of the scarring left by radiation. In a review of 40 studies, narrowing of the bladder-urethra junction occurred in 7% to 41%, rectal injury in 0% to 28%, continence ranged from 21% to 90%, and 80% to 100% of men had erectile dysfunction.4 The European guideline notes that these complications seem less common with the robot than with open surgery.2
Can HIFU or cryotherapy be used as salvage after radiotherapy?+
For very selected cases with biopsy-confirmed recurrence, but the European guideline recommends using them within clinical trials or well-designed prospective cohorts.2 In a large review, the chance of remaining free of PSA recurrence at 5 years was similar across salvage options, from 50% to 60%.7
Who performs salvage prostatectomy in São Paulo?+
I perform salvage radical prostatectomy after radiotherapy when necessary, always with the robot, and the selection is decided case by case. I am a urologist and robotic surgeon in São Paulo, Brazil, with a PhD from the University of São Paulo Medical School and more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. The first consultation can be online, in English.
References
- Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-974. PubMed
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment (PSA recurrence after treatment with curative intent). European Association of Urology; 2026. EAU
- Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019;5(6):856-863. PubMed
- Chade DC, Eastham J, Graefen M, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol. 2012;61(5):961-971. PubMed
- Chade DC, Shariat SF, Cronin AM, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011;60(2):205-210. PubMed
- Moschovas MC, Bravi CA, Dell'Oglio P, et al. Outcomes of Salvage Robotic-assisted Radical Prostatectomy in the last decade: systematic review and perspectives of referral centers. Int Braz J Urol. 2023;49(6):677-687. PubMed
- Valle LF, Lehrer EJ, Markovic D, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021;80(3):280-292. PubMed
- Miszczyk M, Mastroleo F, Kujawska A, et al. Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis. JAMA Oncol. 2026;12(6):637-647. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
